Literature DB >> 24614094

Anticancer drug development: moving away from the old habits.

Felipe Ades1, Dimitrios Zardavas, Philippe Aftimos, Ahmad Awada.   

Abstract

Mesh：

Substances：

Year:  2014        PMID： 24614094     DOI： 10.1097/CCO.0000000000000076

Source DB:  PubMed          Journal:  Curr Opin Oncol        ISSN： 1040-8746            Impact factor:   3.645


× No keyword cloud information.
  5 in total

Review 1.  Clinical management of breast cancer heterogeneity.

Authors:  Dimitrios Zardavas; Alexandre Irrthum; Charles Swanton; Martine Piccart
Journal:  Nat Rev Clin Oncol       Date:  2015-04-21       Impact factor: 66.675

Review 2.  Evaluation of targeted therapies in advanced breast cancer: the need for large-scale molecular screening and transformative clinical trial designs.

Authors:  Z Fadoukhair; D Zardavas; M A Chad; T Goulioti; P Aftimos; M Piccart
Journal:  Oncogene       Date:  2015-06-29       Impact factor: 9.867

3.  WHO, RECIST, and immune-related response criteria: is it time to revisit pembrolizumab results?

Authors:  Felipe Ades; Nise Yamaguchi
Journal:  Ecancermedicalscience       Date:  2015-12-03

4.  Feasibility Study of EndoTAG-1, a Tumor Endothelial Targeting Agent, in Combination with Paclitaxel followed by FEC as Induction Therapy in HER2-Negative Breast Cancer.

Authors:  Michail Ignatiadis; Dimitrios Zardavas; Marc Lemort; Celine Wilke; Marie-Catherine Vanderbeeken; Veronique D'Hondt; Evandro De Azambuja; Andrea Gombos; Fabienne Lebrun; Lissandra Dal Lago; Fanny Bustin; Marion Maetens; Lieveke Ameye; Isabelle Veys; Stefan Michiels; Marianne Paesmans; Denis Larsimont; Christos Sotiriou; Jean-Marie Nogaret; Martine Piccart; Ahmad Awada
Journal:  PLoS One       Date:  2016-07-25       Impact factor: 3.240

5.  New generation of breast cancer clinical trials implementing molecular profiling.

Authors:  Dimitrios Zardavas; Martine Piccart-Gebhart
Journal:  Cancer Biol Med       Date:  2016-06       Impact factor: 4.248
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.